|
Association of British Clinicial Diabetologists
1 Day-to-day variability of fasting self-measured blood glucose associates with risk of hypoglycaemia in adults with type 1 and type 2 diabetes Bailey TS (1), Bhargava A (2), DeVries JH (3), Gerety G (4), Gumprecht J (5), Lane W (6), Wysham CH (7), Bak BA (8), Hachmann-Nielsen E (9), Walker M (10), Philis-Tsimikas A (11).
(1) AMCR Institute, Escondido, CA, USA 2 Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal–bolus therapy in patients with type 2 diabetes: DUAL VII trial Billings LK (1), Oviedo A (2), Rodbard HW (3), Tentolouris N (4), Grøn R (5), Halladin N (6), Walker M (7), Jódar E (8).
(1) NorthShore University HealthSystem, Evanston, IL; University of Chicago Pritzker School of Medicine, Chicago, IL, USA 3 World travel with Type-1 diabetes Alex Charlton A (1), Jessica Charlton J (1). (1) University Hospitals of Leicester, Camp Charnwood 4 Longer acting basal insulin analogues ‘Toujeo’ and ‘Tresiba’ reduce treatment side effects; a therapeutic advance in selected patients Koh WS (1), Shotliff K (1), Feher MD (1). (1) Beta Cell Diabetes Centre, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK 5 Lower glucose variability and risk for hypoglycaemia on insulin Glargine 300 U/mL versus insulin Glargine 100 U/mL, evaluated by the low blood glucose index in randomized phase lll clinical crials Kovatchev BP (1), Meng Z (2), Breton MD (3), Leroy B (4), Cali A (4).
(1) Center for Diabetes Technology, University of Virginia, Charlottesville, VA, US 6 Onset 1: efficacy and safety of mealtime fast‑acting insulin aspart versus insulin aspart after 52 weeks Mathieu C (1), Bruce Bode B (2), Franek E (3), Philis-Tsimikas A (4), Rose L (5), Graungaard T (6), Østerskov AB (7), Azizuddin S (8), Russell-Jones D (9).
(1) UZ Leuven, Leuven, Belgium 7 Achievement of HbA1c targets in the diabetes unmet need with basal insulin Evaluation (DUNE) real-world study Meneghini L (1,2), Mauricio D (3), Orsi E(4) , Cali A (5), Westerbacka J (5), Stella P (5), Candelas C (5), Pilorget V (5), Perfetti R (6), Khunti K (7).
(1) University of Texas Southwestern Medical Center, Dallas, TX, USA 8 Cost-effectiveness of insulin GLARGINE 300 Units/ML (GLA-300) VS Insulin DEGLUDEC 100 Units/ML (IDEG) in T2D Murphy DR (1), Yu X (1), Fournier M (2), Klein TM (1), Fan T (3), Perk S (1), Preblick R (3), Zhou FL (3)
(1) Medical DEecision Modelling INC., Indianapolis, IN, USA 9 Modelling subcutaneous absorption of U100 and U300 insulin GLARGINE in type 1 diabetes Schiavon M (1), Visentin R (1), Dalla Man C (1) Klabunde T (2), Cobelli C (1).
(1) Department of Information Engineering, University of Padova, Padova, Italy 10 Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin Glargine 300 U/ML (GLA-300) from insulin Glargine 100 U/ML (GLA-100) in real-world US treatment settings
Ye F(1), Zhou FL (1), Xie L (2), Kariburyo F (2), Meneghini LF (3). |
